Board of Directors

Amyris delivers high-performance alternatives to petroleum, plant and animal-based products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability. We are making better chemistry biologically.

John Doerr

John Doerr is a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, since 1980. Mr. Doerr currently serves on the board of directors of Google Inc., as well as on the boards of directors of several private companies. Previously, Mr. Doerr served on the board of directors of, Inc. Mr. Doerr holds Bachelor of Science and Master of Science in Electrical Engineering degrees from Rice University and a Master of Business Administration degree from Harvard University.

Chair of the Nominating and Governance Committee

Geoffrey Duyk M.D., Ph.D

Dr. Duyk is partner at Circularis Partners, an investment firm focused on supporting technology-enabled companies that advance the circular economy, promote sustainability, and enhance resource efficiency. Prior to Circularis, Dr. Duyk was the managing director and partner of TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology from 2004 to 2017. Prior to joining TPG, Dr. Duyk served on the Board of Directors and was President of Research and Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals and served as Vice President of Genomics. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics, and an Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from HHMI. He is a Fellow of the American Association for the Advancement of Science. Dr. Duyk currently serves on the Board of Directors of Anuvia Plant Nutrients; Concentric; and Regen. He is a trustee of Case Western Reserve University where he Chairs the finance committee and is a member of the executive committee. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he Chairs the R&D committee. He previously served on the Board of Directors of the American Society of Human Genetics (ASHG) where he is currently a member of the organization’s finance committee and Chairs the investment committee. Dr. Duyk is a member of the Scientific Advisory Board (SAB) for Lawrence Berkeley National Lab (DOE). Previously, he served as a member of the SAB for Bayer CropSciences, Jackson Labs, as well as numerous NIH advisory committees.

Member of the Operations and Finance Committee.
Member of the Audit Committee

Philip Eykerman

Mr. Eykerman joined DSM in 2011 as Executive Vice-President, Corporate Strategy & Acquisitions. In this role, he is responsible for corporate and business group strategy development, budgeting and planning, improvement programs, and all M&A activities. In 2015, he was also appointed as a member of the DSM Executive Committee and at present is responsible for DSM Hydrocolloids as well as DSM Food Specialties activities. Next to these roles within DSM, he is also a Supervisory Board member of ChemicaInvest (DSM/CVC JV), a Supervisory Board member of AnQore TopCo B.V, and a Supervisory Board member of AOC Aliancys (DSM/CVC JV). Before joining DSM, Mr. Eykerman worked for 14 years at McKinsey & Company of which the last 9 year as a Partner and leader of McKinsey’s Chemicals Practice in the Benelux and France. He holds a master degree in Chemical Engineering from the KU Leuven (Belgium) and in Refinery Engineering from the Institut Francais du Pétrole (France).

Christoph Goppelsroeder

Mr. Goppelsroeder has served as the President and CEO of DSM Nutritional Products Ltd. since 2013 and is a member of the DSM Executive Committee. Mr. Goppelsroeder has previously worked at Boston Consulting, Syngenta in its seed care business unit, and F. Hoffman-La Roche in its fine chemicals and vitamins division until the acquisition of such division by DSM in 2003. Mr. Goppelsroeder holds a degree in engineering from the Swiss Federal Institute of Technology and a Master of Business Administration degree from Insead, Fontainebleau.

Dr. Frank Kung

Dr. Kung is a founding member of Vivo, a global healthcare investment firm founded in 1996 in Palo Alto, California. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1983 he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung holds a Bachelor of Science degree in chemistry from the National Tsing Hua University in Taiwan, and a Doctor of Philosophy degree in molecular biology and a Master of Business Administration degree from the University of California, Berkeley. Dr. Kung currently serves on the board of directors of a number of healthcare and biotechnology companies.

Member of the Operations and Finance Committee.

James McCann

Director, 1-800-FLOWERS.COM


Mr. McCann is the founder and chairman of the board of directors of 1-800-FLOWERS.COM, Inc., a floral and gourmet foods gift retailer. Mr. McCann also serves as a director and chair of the nominating and corporate governance committee of IGT PLC and as a director of The Scotts Miracle-Gro Company.

Member of the Audit Committee
Member of the Operations and Finance Committee

John Melo

John Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum) most recently as President of U.S. fuels operations where he successfully led a business transformation and significantly improved the financial performance. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young. Mr. Melo currently serves on the board of directors of Renmatix Inc., serves on the board of directors of BayBio, serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. When not working on the mission of making sustainable chemistry mainstream or championing the eradication of malaria, John enjoys skiing, reading and time with his family on the island of Pico in the Azores, his childhood home.

Steve Mills

Mr. Mills has 40 years of experience in the fields of accounting, corporate finance, strategic planning, risk management, and mergers and acquisitions. He served as Chief Financial Officer of the Company from May 2012 to December 2013. Prior to joining the Company, Mr. Mills had a 33-year career at Archer-Daniels-Midland Company (“ADM”), one of the world’s largest agricultural processors and food ingredient providers. At ADM, he held various senior executive roles, including Chief Financial Officer, Controller, and head of Global Strategic Planning. Since 2013, Mr. Mills has served as a consultant and advisor to clients in the private equity, agribusiness, and financial services fields. Mr. Mills currently serves on the boards of Black Hills Corporation (where he serves as the lead director), Farmers Edge, Inc., Illinois College (where he also serves as the chairman of the board), First Illinois Corporation (along with its wholly-owned banking subsidiary, Hickory Point Bank & Trust) and Arianna S.A. Mr. Mills holds a Bachelor of Science degree in Mathematics from Illinois College.

Chair of the Audit Committee
Chair of the Operations and Finance Committee.
Member of the Leadership, Development, Inclusion and Compensation Committee.

Carole Piwnica

Ms. Piwnica is director of NAXOS S.A.R.L. (Switzerland), a consulting firm advising private investors and Rothschild & Co (financial services, France), and the chairman of Arianna S.A. (financial services, Luxemburg). Previously, Ms. Piwnica served as a director, from 1996 to July 2006, and Vice-Chairman of Governmental Affairs, from 2000 to 2006, of Tate & Lyle Plc, a European food and agricultural ingredients company. She was a chairman of Amylum Group, a European food ingredient company and affiliate of Tate & Lyle Plc, from 1996 to 2000. Ms. Piwnica was a member of the board of directors of Aviva plc, a British insurance company, from May 2003 to December 2011, a member of the Biotech Advisory Council of Monsanto from May 2006 to October 2009, a member of the board of directors of Dairy Crest from 2007 until 2010, a member of the board of directors of Toepfer Gmbh from 1996 until 2010 and a member of the board of directors of Eutelsat (satellites, France) from 2010 until 2019. In 2010, she was appointed as a member of the board Sanofi (pharmaceuticals, France). Ms. Piwnica holds a Law degree from the Université Libre de Bruxelles and a Master of Laws degree from New York University. She has also been a member of the bar association of the state of New York, USA from 1985 until 2019.

Chair of the Leadership, Development, Inclusion and Compensation Committee.
Member of the Operations and Finance Committee.
Member of the Nominating and Governance Committee

Lisa Qi

Director, Daling Family


Lisa has pioneered the development of feminine Chinese brands for Daling Family. She partnered with former Estee Lauder CTO, Harvey Gedeon and award-winning Harvard Medical School skin management expert Dr. Rothaus, founding La Nature Research Center in New York. Together they created the Native Beauty skin wellness line. With Rosa Dwyer, ex-chief of formula for Estée Lauder Group, she developed Color Lock – a wellness line specially formulated for Chinese women's skin. Prior to Daling, Lisa served as Brand Director of Dupont Lycra (Hong Kong & China) and lead it to its current top-of-market position in China. She then served as the youngest Chief Representative of YSL China in France in the company’s history. 

Julie Spencer Washington


Julie Spencer Washington is an accomplished senior executive with a distinguished career in marketing spanning leading companies like Trinity Health, Champion Petfoods, Procter & Gamble, Gillette, Nestlé Purina, Jamba Juice, and Luxottica. In each of her leadership positions, Julie has driven sustainable corporate growth and profitability through a keen understanding of consumer needs and behaviors, market dynamics and digital trends (including social media). Julie has also leveraged her special gift for developing and motivating high-performing teams to further impact corporate success.

Currently, Julie serves as Chief Marketing & Communications Officer at Trinity Health, a Catholic health care delivery system that serves more than 30 million people across 22 states. She is responsible for the strategic leadership of marketing, brand building, demand creation, internal and crisis communications and community engagement.

Julie is committed to community improvement and, in parallel with her professional responsibilities, has a long, varied history of board service. She currently serves on the board of directors of Union Institute and University. Julie’s professional and community accomplishments have earned national attention, including selection of Black Enterprise’s “Top Women Executives in Advertising & Marketing ” (2016 and 2013),  Savoy magazine’s “Top 100 Most Influential Blacks in Corporate America” (2020, 2018 and 2010), and Marketers That Matter’s “Top B2C Marketing Executive of the Year” (2013).

Julie holds a Master of Business Administration degree from Washington University, a Bachelor of Arts degree in Chemistry and Psychology from Emory University, and an Executive in Education Certificate on Driving Digital and Social Strategy from Harvard University. A champion of diversity and inclusion, Julie has helped companies build more effective teams.

Member of the Leadership, Development, Inclusion and Compensation Committee.

Patrick Yang Ph.D.


Dr. Patrick Y. Yang was appointed to the Board of Amyris, effective July 1, 2014. From September 2017 to January 2019, he was executive Vice-President of Juno Therapeutics. From January 2010 to March 2013, he served as Head of Global Technical Operations for F. Hoffmann-La Roche Ltd. where he was responsible for the company's pharmaceutical manufacturing, process development, engineering, quality, regulatory, supply chain and procurement. Before joining Roche, he worked for Genentech, Merck & Co., General Electric and Life Systems, during which time he developed significant experience with pharmaceuticals and biotechnology manufacturing, engineering, technology, and supply chain management. Dr. Yang served on the board of directors of Tesoro Corporation, a public independent petroleum refining and marketing company, from December 2010 to October 2018. He currently serves on the board of Codexis, a public company that develops biocatalysts for the pharmaceutical and fine chemicals markets, since February 2014; and PharmaEssentia Corporation, a clinical-stage biotechnology company, since March 2014; and previously served on the board of TaiMed, Inc. in 2007-2009; and Celladon Corporation in 2014-2015: both are clinical-stage biotechnology companies.  Dr. Yang earned a Bachelor of Science in Engineering from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati and a Ph.D. in engineering from the Ohio State University.

Member of the Leadership, Development, Inclusion and Compensation Committee.